Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 8, Issue 4, Pages 527-540Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.8.4.527
Keywords
acute myeloid leukaemia; acute promyelocytic leukaemia; gemtuzumab ozogamicin; immunoconjugate; monoclonal antibodies
Ask authors/readers for more resources
Background: Gemtuzumab ozogamicin consists of a semisynthetic derivative of calicheamicin, a potent cytotoxic antibiotic, linked to a humanized anti-CD33 monoclonal antibody. Objectives: To describe the pharmacology of gemtuzumab ozogamicin and to provide an overview of clinical trials in acute myeloid leukaemia. Methods: Review and summary of publications on gemtuzumab ozogamicin indexed in the PubMed electronic database. Results/conclusions: Gemtuzumab ozogamicin has shown moderate activity as a single agent in patients with CD33-positive refractory or relapsed acute myeloid leukaemia, with more promising results in acute promyelocytic leukaemia. The side effect profile may be an improvement on conventional chemotherapy, except for a higher frequency of veno-occlusive disease or sinusoidal obstructive syndrome, especially after a subsequent haematopoietic stem cell transplantation. Because of the different mechanisms of action and non-overlapping toxicities, the integration of this immunoconjugate with standard chemotherapy is a rational approach, and Phase III trials are ongoing both in the induction and in the post-remission settings.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available